Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.52 USD | 0.00% | 0.00% | -30.99% |
Business Summary
Number of employees: 67
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Proprietary Prodrugs
100.0
%
| 10 | 100.0 % | 27 | 100.0 % | +162.58% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Europe
100.0
%
| 10 | 100.0 % | 27 | 100.0 % | +162.58% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Christal Mickle
FOU | Founder | 45 | 30/06/30 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 10/23/10 |
R. Clifton
DFI | Director of Finance/CFO | 51 | 01/15/01 |
Daniel Gallo
CTO | Chief Tech/Sci/R&D Officer | - | 31/23/31 |
Adrian Quartel
CTO | Chief Tech/Sci/R&D Officer | 63 | 04/01 |
Sven Guenther
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/07/01 |
Nichol Ochsner
IRC | Investor Relations Contact | - | 09/22/09 |
Abbi Maher
LAW | General Counsel | - | 31/23/31 |
Joshua Schafer
PRN | Corporate Officer/Principal | 53 | 09/23/09 |
Comptroller/Controller/Auditor | 40 | 13/17/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 25/23/25 |
Tamara Favorito
CHM | Chairman | 65 | 18/21/18 |
Director/Board Member | 56 | 25/23/25 | |
Christal Mickle
FOU | Founder | 45 | 30/06/30 |
Sven Guenther
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/07/01 |
Corey Watton
BRD | Director/Board Member | 54 | 25/23/25 |
John Bode
BRD | Director/Board Member | 49 | 25/23/25 |
Thomas Anderson
BRD | Director/Board Member | 68 | 07/23/07 |
Alvin Shih
BRD | Director/Board Member | 47 | 20/01 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 10/23/10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,001,878 | 39,916,898 ( 88.70 %) | 1,575,692 ( 3.501 %) | 88.70 % |
Company contact information
Zevra Therapeutics, Inc.
1180 Celebration Boulevard Suite 103
34747, Celebration
+321 939 3416
http://zevra.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.99% | 189M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- ZVRA Stock
- Company Zevra Therapeutics, Inc.